Cipla is a stage closer to making headway in the multi-billion-dollar Advair Diskus (fluticasone/salmeterol) market in the US, after wrapping up successfully its Phase III clinical trial to demonstrate equivalence between the Indian firm’s proposed generic product and GlaxoSmithKline’s powerhouse brand.
The Indian firm’s management recently told investors that readout of the trial results – “conducted over a period of 15...




